• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Arixtra

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Arixtra

  • Profile

Profile

Contact Information

Contact: Viatris
Website: https://www.viatris.com/en/search?q=arixtra

Currently Enrolling Trials

    Show More

    General Information

    Arixtra, an injectable solution for subcutaneous use, has been approved as a preventative treatment for deep vein thrombosis (DVT) in adults undergoing hip fracture, hip replacement, or knee replacement surgery. It is adminstered through a single dose, prefilled syringe, affixed with an automatic needle protection system. Arixtra is the only antithrombotic agent approved in the United States for hip fracture surgery.

    DVT is caused by a blood clot forming in a deep vein in the leg. It may cause pain and swelling, and enlargement and discoloration of the veins. The clot can grow in size and block other veins. Most seriously, portions of the clot may break away and travel through the veins to the lungs, leading to a life threatening pulmonary embolism.

    Clinical Results

    International randomized, double-blind phase III trials evaluated the use of Arixtra in more than 7,000 subjects undergoing hip fracture, hip replacement or knee replacement surgeries. Results demonstrated Arixtra to provide a superior benefit in comparison to the reference treatment.

    Side Effects

    Adverse events associated with the use of Arixtra may include (but are not limited to) the following:


    • Bleeding complications
    • Mild irritation at injection site
    • Anemia
    • Fever
    • Nausea
    • Edema
    • Constipation

    Mechanism of Action

    Arixtra (fondaparinux sodium) exhibits antithrombotic activity, which is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium activates the innate neutralization of Factor Xa by ATIII. This neutralization interupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development.

    Additional Information

    For additional information on Arixtra, please visit Sanofi-Synthelabo.

    Approval Date: 2001-12-01
    Company Name: Viatris
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing